be a leading cause of inappropriate treatment or misdiagnosis.
INTRODUCTION
Interfering substances are considered a significant source of error in clinical laboratory measurements [1] . Such interference may Beckman Coulter AU5800를 이용한 용혈, 고빌리루빈혈증, 고지방혈증에 의한 간섭영향 HIL 인덱스의 수정안 제안 ferents is subjective and has demonstrated little agreement between the actual concentration of each interferent and the assigned grade of turbidity, hemolysis, or icterus [3] . To overcome these disadvantages, automated HIL-indices were introduced and adopted in clinical laboratories. The Beckman Coulter AU5800 (Beckman Coulter, Brea, CA, USA) is a recently introduced chemistry analyzer equipped with HIL systems that can detect and semi-quantify the interference of hemolysis, icterus, and lipemia. This analyzer can quantify the serum condition by spectrophotometric measurements using several wavelengths. It also presents the interfering substances as index values according to mathematical algorithms.
Although several studies have evaluated the interfering effects of hemolysis, icterus, and lipemia [4] [5] [6] , there are only a few documents specifying the proper methods to perform interference studies [2] . In 2012, the Clinical and Laboratory Standards Institute (CLSI) published guidelines for HIL-indices to enhance the accuracy of reported patient test reports [7] . This document provided detailed protocols on establishing HIL-indices, estimating interference effects of HIL, and reporting interference effects of HIL. Therefore, the aim of our study was to evaluate the interference effect of hemolysis, icterus, and lipemia on routine chemistry assays and the performance of AU5800 HIL systems according to the CLSI guidelines C56-A and EP7-A2 [7, 8] . In addition, based on the results of our interference study, we established the HIL-index for each analyte and assessed the practicality of the CLSI guideline for clinical laboratories.
MATERIALS AND METHODS

Chemistry Analyzer
The Beckman Coulter AU5800 clinical chemistry analyzer (Beckman Coulter, Brea, CA, USA) is a novel fully automated analytical platform designed for the analysis of routine chemistry assays, immunoassays, and therapeutic drugs. The AU5800 analyzer is also able to detect hemolysis, icterus, and lipemia in samples. It is programmed to generate semi-quantitative index values as a measure of the concentration of these interfering substances (Table 1) . Patient samples are diluted with the LIH reagent and the absorbance is measured at 6 unique wavelengths: 410/480 nm and 600/800 nm for hemolysis, 480/570 nm and 600/800 nm for icterus, and 660/800 nm for lipemia. This spectrophotometric method estimates the levels of hemoglobin, bilirubin, and lipid, which have distinct absorption spectra. If one or more chromogen in the potentially interfering concentration is present in a sample, semi-quantitative index values are reported along with the results of the sample.
Measured Analytes
The following 35 analytes were measured: total protein, albumin, total bilirubin, direct bilirubin, blood urea nitrogen (BUN), uric acid, alkaline phosphatase (ALP), inorganic phosphorous (IP), magnesium, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), lipase, phospholipid, glucose, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), total calcium, amylase, creatine kinase (CK), sodium, potassium, chloride, iron, unsaturated iron binding capacity (UIBC), total cholesterol, bicarbonate, C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), ethanol, ammonia, and ketone bodies (KB).
Interference Testing
According to the CLSI document EP7-A2 [8] , we evaluated the effects of hemolysis, icterus, and lipemia by adding hemoglobin, bilirubin, and Intralipid to serum pools with known analyte concentrations. Interference testing was performed at two different medical decision levels of the analytes. Pooled sera were prepared as test samples, and all were inspected by the naked eye to ensure the absence of interferents, except for pooled sera containing high bilirubin and lipid concentrations. To establish the interference effects of hemolysis, icterus, and lipemia/turbidity, 24 different serum pools including different concentrations of analytes were prepared and mixed with hemoglobin-, bilirubin-or Intralipid-stock solutions. Hemoglobin-stock solution was prepared by adding purified hemoglobin (Sigma-Aldrich, MO, USA) to distilled water. Bilirubin powder (Sigma-Aldrich, MO, USA) mixed with di- methyl sulfoxide was used to prepare the bilirubin-stock solution.
Intralipid (20%) (Sigma-Aldrich, MO, USA) was used as the stock solution for evaluating the lipemia/turbidity effect. Although Intralipid was not equivalent to the lipemic effect in vivo, it has been considered the best substitute for interference studies [9] . To determine the relationship between interferent concentration and the magnitude of interference, eight samples with increasing concentrations of interferent were prepared by mixing with the pooled sera and stock solutions. To minimize the potential interference due to the reduction of an endogenous substance, the stock solution was diluted to no more than 5% of the pooled serum. Each sample was measured over 2 days, with one run per day. The percent of change was calculated from baseline concentrations. This study was performed with the approval of the institutional review boards of Chung-Ang University Hospital.
Acceptability Criteria for Evaluating the Interference Effects
We defined analytically significant interference when the bias in the presence of the interfering substance differed by more than the desirable analytic goal. The desirable analytic goal was calculated as one-half of the average biological variation, and was termed the cut-off bias (Bcut-off) to evaluate the interference effect. This parameter has also been called the tolerable analytical variation, and has been used to generate quality specifications [10, 11] . To calculate Bcut-off, the within-subject biological variation (CVw) was adopted from the Westgard QC website [12] . If there were no available data for CVw, Bcut-off was arbitrarily set to 10%. Table 2 
Statistical Analysis
Statistical analysis of the correlation between the interferent concentration and the magnitude of interference was performed using the linear least square regression analysis. All statistical analyses were performed using SigmaPlot 12.0 (Systat Software Inc., CA, USA).
RESULTS
The relationship between the concentration of the three interferents and the reported HIL-indices is summarized in Table 3 . Al- Bcut-off: Cut-off bias calculated based on the desirable analytic goal. *Arbitrarily set to 10% owing to a lack of within-subject biological variation data. though all of the three indices did not precisely match the corresponding interferent concentrations, an increasing trend in the indices was observed with increased concentrations of interferent. (Table 4) . Specifically, interference was observed with magnesium at very low concentrations of hemoglobin (H-index, 0). In addition, most analytes were affected by lower hemoglobin concentrations compared to the H-indexTD calculated from technical documents provided by the manufacturer. As expected (Table 5) , total and direct bilirubin levels were increased with the addition of purified bilirubin, and magnesium. Moreover, ammonia also falsely increased. A decrease in total protein, creatinine, and total cholesterol by bilirubin interference was observed. For samples with added Intralipid (Table 6) , the results for albumin, IP, magnesium, triglyceride, phospholipid, iron, and ammonia showed positive interference by Intralipid, whereas total protein, uric acid, HDL, LDL, and creatinine were inversely affected by Intralipid. Triglyceride and phospholipid levels were increased as expected; however, HDL and LDL decreased. Total cholesterol was not affected by Intralipid, but was negatively affected by bilirubin. Total protein was affected by all three interferents, of which hemoglobin had a positive effect, and bilirubin and Intralipid had negative effects. Magnesium also exhibited positive interference by all three interferents. Ammonia was positively affected, whereas creatinine was negatively affected by both bilirubin and Intralipid.
Albumin and IP were positively affected by both hemoglobin and Intralipids, and uric acid was negatively affected by Intralipid. For most analytes, we found that the HIL-index calculated in this study was lower than those described in the evaluated technical documents.
DISCUSSION
A major goal of clinical laboratories is to produce accurate and precise results. However, endogenous compounds that affect chemical measurements in various ways are considered a significant source of error. Particularly, hemolysis, icterus, and lipemia may be the most common interferents related to sample integrity [5] .
Therefore, it has been crucial for a long time for clinical laboratory staff to visually inspect samples owing to the possibility of interference caused by these substances. However, visual inspection is subjective and does not accurately detect the presence of endogenous interferents [13] . An automated detection system for these interferents, the HIL system, provides an objective and con- I-indexTD: I-index from the technical document provided by the manufacturer. I-index1: I-index calculated from the level 1 sample. I-index2: I-index calculated from the level 2 sample. *Not specified in the technical document. Table 6 . Items affected by Intralipid; comparing the L-indexTD obtained with AU5800 and the L-index calculated in this study for each analyte
Increasing that are subject to drift and failure. This study therefore serves as a valuable example about establishing and validating the HIL-index for automated chemistry analyzers. We expect that our results can be applied by all laboratories that use AU5800 or other Beckman Coulter automated chemistry analyzers.
When introducing an HIL system, it is critical to determine how much bias is clinically significant. In the CLSI guideline C56-A, the acceptability criteria are derived from the biological variation of the analyte and the precision of the measurement system [7] . According to this guideline, the acceptability criteria are calculated from pooled variation (√(within-subject variation) 2 + (precision)
2 ) multiplied by 1.96, which is the approximate value of the 97.5 percentile point of the normal distribution. With this formula, the acceptability criteria would be approximately 2-3 times higher than the precision when biological variation is equal to or lower than the precision. This approach is statistically reasonable, and these criteria have been widely applied [6, 10] . However, the within-subject variation is generally much larger than the analytical imprecision. Therefore, the acceptability criteria described in the CLSI guideline C56-A is approximately twice as much as the within-subject variation [14] . This indicates that more than 50% bias could be allowed in some analytes. In the CLSI guideline C56-A, the acceptability criteria for direct bilirubin and lipase were calculated as 72.3% and 63.3%, respectively. Although this approach is statistically reasonable, no clinical laboratory director can easily apply these acceptability criteria to ensure accurate and precise results with interfering substances.
As an alternative, desirable analytic goals can be used as appropriate interference criteria. The criteria are facilitated by a simple calculation consisting of 50% within-subject variation and easy access to the database on biological variation [12, 15] . Compared to the cut-off concentrations calculated in the CLSI guideline C56-A, desirable analytic goals were generally less than half of the previously specified cut-off concentrations. With this criterion, information that is more robust can be obtained about the existence of interfering substances in samples, which would better prevent pre-analytical errors in many clinical laboratories. However, the application of desirable analytic goals also has limitations due to lack of knowledge concerning biological variation. Although we empirically applied 10% as the criteria for the analytes in this study, there is no evidence that 10% bias originating from interferents is allowable. In addition, the allowable interference is set to 5% or 10% in batches obtained from manufacturers [16] . Since a variety of applicable criteria exist, each laboratory should carefully select the appropriate acceptability criteria depending on its needs, because there is no general consensus on which criteria is most suitable for specific analytes [17] . However, it should be noted that more stringent quality goals would be advantageous in reflecting sample quality.
There are some limitations in this study. [19] . In this study, the effect of Intralipid varied depending on the type of lipids involved. Triglyceride and phospholipid were increased with spiking Intralipid containing these analytes. However, HDL and LDL decreased due to the volume effect of Intralipid [20] .
In this study, we evaluated the effects of hemolysis, icterus, and lipemia on clinical chemistry assays with AU5800, and established HIL-indices for each analyte according to the CLSI guideline. These HIL-indices can provide an effective screening method for the verification of specimen quality. However, the interference effect could be interpreted with various criteria. Furthermore, the amount of interference is clinically significant when adopting the HIL-index in the clinical laboratory. 
